世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の皮膚治療薬市場 2018-2022年

Global Dermatological Drugs Market 2018-2022

IRTNTR23475

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年10月US$2,500
シングルユーザライセンス
105

サマリー

この調査レポートは世界の皮膚治療薬市場を分析・予測したTechNavioの市場調査報告書です。

Description

About Dermatological Drugs
Dermatology is a therapy area that deals with diseases of the skin, hair, and nails, where the most common conditions are psoriasis, eczema, and acne vulgaris. Apart from these, there are around 3,000 types of dermatologic conditions.
Technavio’s analysts forecast the Global Dermatological Drugs Market to grow at a CAGR of 11.19% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the dermatological drugs market. To calculate the market size, the report considers the revenue generated from the sales of dermatological drugs.

Technavio's report, dermatological drugs market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Key vendors
- AbbVie
- Offering
- Description
- Amgen
- Celgene
- Johnson & Johnson

Market driver
- Emergence of improved diagnostic modalities
- For a full, detailed list, view our report
Market challenge
- Patient non-adherence to treatment
- For a full, detailed list, view our report

Market trend
- Patent expiry of major drugs
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: PIPELINE ANALYSIS
- Pipeline analysis
PART 06: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 08: MARKET SEGMENTATION BY APPLICATION
- Segmentation by application
- Eczema
- Psoriasis
- Acne
- Skin infections
- Others
PART 09: MARKET SEGMENTATION BY PRODUCT
- Segmentation by product
- Comparison by product
- Biologics - Market size and forecast 2017-2022
- Small molecules - Market size and forecast 2017-2022
- Market opportunity by product
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 14: MARKET TRENDS
- Increase in prices of dermatological drugs
- Patent expiry of major drugs
- Availability of biologics/biosimilars for treatment
- Increasing research on gene therapy
PART 15: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 16: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AbbVie
- Offering
- Description
- Amgen
- Celgene
- Johnson & Johnson
PART 17: APPENDIX
- List of abbreviations


Exhibit 01: Parent market
Exhibit 02: Global pharmaceutical drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Potential phase III agents for eczema, psoriasis, acne, and skin infection
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global dermatological drugs market - Market size and forecast 2017-2022 ($ bn)
Exhibit 10: Global dermatological drugs market - Year over year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2017
Exhibit 19: Global dermatological drugs market by product - Market share 2017-2022 (%)
Exhibit 20: Comparison by product
Exhibit 21: Global dermatological drugs market by biologics - Market size and forecast 2017-2022 ($ bn)
Exhibit 22: Global dermatological drugs market by biologics - Year over year growth 2018-2022 (%)
Exhibit 23: Global dermatological drugs market by small molecules - Market size and forecast 2017-2022 ($ bn)
Exhibit 24: Global dermatological drugs market by small molecules - Year over year growth 2018-2022 (%)
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Global dermatological drugs market by region - Market share 2017-2022 (%)
Exhibit 28: Regional comparison
Exhibit 29: Dermatological drugs market in Americas - Market size and forecast 2017-2022 ($ bn)
Exhibit 30: Dermatological drugs market in Americas - Year over year growth 2018-2022 (%)
Exhibit 31: Top three countries in Americas
Exhibit 32: Dermatological drugs market in EMEA - Market size and forecast 2017-2022 ($ bn)
Exhibit 33: Dermatological drugs market in EMEA - Year over year growth 2018-2022 (%)
Exhibit 34: Top three countries in EMEA
Exhibit 35: Dermatological drugs market in APAC - Market size and forecast 2017-2022 ($ bn)
Exhibit 36: Dermatological drugs market in APAC - Year over year growth 2018-2022 (%)
Exhibit 37: Top three countries in APAC
Exhibit 38: Market opportunity
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: AbbVie overview
Exhibit 45: AbbVie - Business segments
Exhibit 46: AbbVie - Organizational developments
Exhibit 47: AbbVie - Geographic focus
Exhibit 48: AbbVie - Key offerings
Exhibit 49: Amgen overview
Exhibit 50: Amgen - Business segments
Exhibit 51: Amgen - Organizational developments
Exhibit 52: Amgen - Geographic focus
Exhibit 53: Amgen - Key offerings
Exhibit 54: Celgene overview
Exhibit 55: Celgene - Business segments
Exhibit 56: Celgene - Organizational developments
Exhibit 57: Celgene - Geographic focus
Exhibit 58: Celgene - Key offerings
Exhibit 59: Johnson & Johnson overview
Exhibit 60: Johnson & Johnson - Business segments
Exhibit 61: Johnson & Johnson - Organizational developments
Exhibit 62: Johnson & Johnson - Geographic focus
Exhibit 63: Johnson & Johnson - Segment focus
Exhibit 64: Johnson & Johnson - Key offerings

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る